In 2020, another pediatric evaluation by Solmaz et al. found higher levels of A1BG, complement factor B, plasminogen, α-2-antiplasmin and inter α-trypsin inhibitor heavy chain H2, and lower levels of centrosomal protein of 290 and F-box/LRR-repeat protein 17 in the sera of pediatric MS patients [145]. This evidence concerns the gene PLG and myeloid sarcoma.